The semi-inhibition rate demonstrates that the estimated IC50 is lower in the high-expression SOX10 group than in the counterpart, which suggests that high-expression SOX10 has higher sensitivity to gefitinib; in other words, gefitinib is more effective in gliomas overexpressing SOX10 (44). Here, SOX10 is linked to glioma.